Lilly Zyprexa “Dear Doctor” Letter Warns Of Classwide Diabetes Risk
Executive Summary
Lilly is notifying health care professionals of a class warning on the risk of diabetes for all atypical antipsychotics, including Zyprexa (olanzapine)
You may also be interested in...
Bristol Diabetes Class Warning For Abilify Cites “Paucity” Of Reports
Bristol-Myers Squibb's Abilify now carries a diabetes class warning for atypical antipsychotics, although the company plans to continue discussions with FDA about modifications as new data become available
Bristol Diabetes Class Warning For Abilify Cites “Paucity” Of Reports
Bristol-Myers Squibb's Abilify now carries a diabetes class warning for atypical antipsychotics, although the company plans to continue discussions with FDA about modifications as new data become available
Geodon, Abilify Have Low Diabetes Risk, ADA Says; Lilly Disagrees
An American Diabetes Association "consensus" statement on antipsychotics and the risk of diabetes may help Pfizer and Bristol-Myers Squibb make the case to FDA to exempt Geodon and Abilify from class labeling